^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Focus V (anlotinib)

    i
    Other names: AL3818, AL-3818, ALTN, AL 3818
    Company:
    Advenchen, Sino Biopharm
    Drug class:
    Multi-tyrosine kinase inhibitor
    Related drugs:
    2d
    RCT of GAPP Induction and Concurrent Chemoradiotherapy for High-risk Locoregionally Advanced NPC. (clinicaltrials.gov)
    P3, N=442, Not yet recruiting, Sun Yat-sen University
    New P3 trial
    |
    cisplatin • gemcitabine • Focus V (anlotinib) • Loqtorzi (toripalimab-tpzi)
    5d
    Benmelstobart Plus Anlotinib Combined With SBRT for Patients With Hepatocellular Carcinoma Failing First-Line Targeted Therapy (clinicaltrials.gov)
    P2, N=29, Not yet recruiting, Nanfang Hospital, Southern Medical University
    New P2 trial
    |
    Focus V (anlotinib) • Andewei (benmelstobart)
    7d
    Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity. (PubMed, Sci Adv)
    In vivo, combined treatment with anlotinib and RAD51-IN-1 significantly reduced tumor burden without notable toxicity. These findings suggest that RAD51-mediated HRR may contribute to anlotinib resistance and support RAD51 inhibition as a promising approach to overcome therapeutic resistance in ovarian cancer.
    Preclinical • Journal
    |
    RAD51 (RAD51 Homolog A)
    |
    EGFR mutation
    |
    Focus V (anlotinib)
    7d
    MET amplification in diffuse pleural mesothelioma and response to savolitinib: a case report. (PubMed, Transl Lung Cancer Res)
    The disease proved refractory to multiple lines of therapy, including platinum-based chemotherapy, immunotherapy, intrathoracic instillation and a subsequent individualized regimen comprising intraperitoneal cisplatin plus sintilimab for local disease control and potential immunomodulation synergized with oral anlotinib. It illustrates that rare but actionable genomic alterations, such as MET amplification, can be identified through liquid or tissue biopsy and can inform successful targeted treatment strategies, even in a tumor type where such alterations are uncommon. Histological classification combined with molecular profiling remains pivotal for personalized oncology.
    Journal • IO biomarker
    |
    MET (MET proto-oncogene, receptor tyrosine kinase) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • BAP1 (BRCA1 Associated Protein 1)
    |
    MET amplification • MET mutation
    |
    cisplatin • Focus V (anlotinib) • Tyvyt (sintilimab) • Orpathys (savolitinib)
    9d
    TQB3616-ALTN-II-01: A Clinical Study of TQB3616 Capsules Combined With Anlotinib Hydrochloride Capsules or Standard Chemotherapy Second-line and Above in the Treatment of Advanced Lung Cancer (clinicaltrials.gov)
    P2, N=21, Terminated, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | N=126 --> 21 | Recruiting --> Terminated; This study was closed due to business reasons. Closure was not prompted by any safety or efficacy concerns.
    Enrollment change • Trial termination
    |
    Focus V (anlotinib) • irinotecan • Saitanxin (culmerciclib)
    13d
    Targeted and molecular therapies in Ewing sarcoma: a comprehensive review of preclinical and clinical advances. (PubMed, Clin Transl Oncol)
    Targeted and molecular therapies in EWS show significant promise, particularly in rational combinations that exploit the tumor's dependence on EWS-FLI1-driven transcriptional dysregulation, DNA damage repair deficiencies, or survival signaling. Future research must prioritize biomarker-driven patient selection, integration of multiomics approaches, and multicenter prospective trials to translate these strategies into clinically meaningful improvements in EWS survival.
    Preclinical • Review • Journal • PARP Biomarker • IO biomarker
    |
    EWSR1 (EWS RNA Binding Protein 1) • AURKA (Aurora kinase A) • FLI1 (Fli-1 Proto-Oncogene ETS Transcription Factor) • CD99 (CD99 Molecule)
    |
    Focus V (anlotinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Yondelis (trabectedin) • Visudyne (verteporfin) • ganitumab (AMG 479) • linsitinib (ASP7487) • ONCT-216 • evofosfamide (IMGS-101) • figitumumab (CP-751,871)
    13d
    MBC-EA: A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurrent/Metastatic Breast Cancer Previously Treated With Antibody-Drug Conjugates (clinicaltrials.gov)
    P2, N=52, Recruiting, Sun Yat-sen University
    New P2 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    Focus V (anlotinib) • Halaven (eribulin mesylate)
    13d
    Efficacy and Safety of Cadonilimab Plus Anlotinib in Advanced STS That Failed the Previous First-line Standard Treatment (clinicaltrials.gov)
    P2, N=27, Recruiting, Second Affiliated Hospital, School of Medicine, Zhejiang University | Trial primary completion date: Apr 2026 --> Dec 2026
    Trial primary completion date
    |
    Focus V (anlotinib) • Kaitanni (cadonilimab)
    14d
    Anlotinib Plus Durvalumab-Platinum-Etoposide in First-line Treatment Extensive Small-cell Lung Cancer (clinicaltrials.gov)
    P2, N=34, Completed, Henan Cancer Hospital | Recruiting --> Completed | N=120 --> 34
    Trial completion • Enrollment change
    |
    Imfinzi (durvalumab) • Focus V (anlotinib) • etoposide IV
    15d
    A Single-arm, Multicenter Exploratory Clinical Trial of Anlotinib Combined With TQB2450 and the SOX Regimen as First-line Treatment for Advanced Gastric Cancer With Low PD-L1 Expression (clinicaltrials.gov)
    P2, N=37, Active, not recruiting, Yongxu Jia | Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2025 --> Jun 2026
    Enrollment closed • Trial primary completion date • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1)
    |
    HER-2 negative
    |
    Focus V (anlotinib) • oxaliplatin • Andewei (benmelstobart) • Teysuno (gimeracil/oteracil/tegafur)
    19d
    A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC (clinicaltrials.gov)
    P2, N=48, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    cisplatin • carboplatin • Focus V (anlotinib) • etoposide IV • Andewei (benmelstobart)